India Can Build Rockets, But Can Its VCs Fund The Next One?

Skyroot Aerospace’s Vikram-1 successfully placed satellites into orbit on July 18, 2026. It became the first privately developed Indian rocket to accomplish an orbital launch. That made the mission a major milestone for India’s private space sector.

The achievement mattered because India’s space programme had historically been dominated by ISRO. Vikram-1 demonstrated that Indian entrepreneurs could develop and launch complex space hardware. It moved private companies from ambition and experimentation into proven orbital capability.

The launch also shaped the article’s wider argument about capital. India has shown that its founders can build advanced technologies, including rockets. The harder question is whether Indian venture capital and private equity will repeatedly finance such difficult, high-risk breakthroughs.

Deeptech generally means technology based on substantial scientific discovery or engineering innovation. Unlike many software products, it often depends on laboratories, hardware, testing, patents, clinical evidence, or regulatory approval. The article uses the term for technologies whose commercial potential may remain uncertain for years.

Rockets require complex engineering, testing, and launch systems. Dognosis is developing canine-assisted cancer detection, which needs clinical validation and regulatory approvals. Advanced hardware similarly requires physical prototypes and technical testing before customers can rely on it. These demands make deeptech slower and more expensive to prove.

This category matters because investors cannot judge every company by early revenue alone. A startup may be creating valuable technology before it has a finished product or paying customers. India’s debate concerns whether investors are willing to finance that uncertain validation process.

Indian deeptech startups raised approximately $500 Mn across 87 deals in 2025. In Q3 2026, they raised $290 Mn across 28 deals. The quarterly figure was up 176% year over year from $105 Mn across 29 deals in Q3 2025.

Funding was therefore measured across deals rather than as an equal amount per company. The article does not provide a company-by-company breakdown. It shows that 87 deals shared or represented the 2025 total, while 28 deals represented the Q3 2026 total.

The comparison also reveals concentration in the latest period. Q3 funding nearly tripled in value, but the number of funded deals declined slightly. Deeptech’s total rose sharply even though fewer transactions were recorded, indicating that funding growth did not automatically reach more startups.

A sector’s total funding measures money raised, not the number of founders who gain access. If larger investments go to a limited number of companies, the headline total can rise while many other startups remain unfunded. The article’s quarterly data shows this distinction clearly.

Deeptech startups raised $290 Mn across 28 deals in Q3 2026, compared with $105 Mn across 29 deals a year earlier. The increase was 176% year over year, but one fewer deal was recorded. The article therefore shows more capital moving through fewer transactions.

This pattern matters for founders building technologies that need years of testing. Greater specialist capital may help selected companies scale, but it does not prove that early-stage or less connected founders can access it. The article links this concern to complaints about pedigree, traction, and slow investment decisions.

Deeptech companies often must prove that a scientific or engineering idea works before they can sell it widely. That process can involve technical testing, clinical validation, prototypes, and regulatory approvals. Revenue may arrive only after these steps are complete.

Dognosis illustrates the problem. It is developing canine-assisted cancer detection technology, and medical technologies can require years of clinical validation and regulatory work. Akash Kulgod said delays caused by repeated meetings or demands for commercial traction hurt the development cycle. Investors asking for revenue first may be asking for proof that requires their funding.

This creates a mismatch between normal commercial expectations and deeptech timelines. Investors may prefer evidence from customers or existing backers, while founders need capital to generate that evidence. The article argues that financing a proven technology and financing the experiment that tests it are different decisions.

India’s technology strength was helped by software-services work that made the country a global technology powerhouse. The article warns that AI could automate parts of that industry. If that happens, relying mainly on established services work could become less secure as an economic foundation.

The alternative is to build and own foundational technologies. India has already shown that its entrepreneurs can create complex systems, with Vikram-1’s orbital launch serving as a powerful example. Deeptech companies are also pursuing medical technologies and advanced hardware, but these ventures need patient, technically informed capital.

The forward challenge is therefore financial as well as technical. India must determine whether venture capital and private equity can repeatedly support difficult breakthroughs, not only invest after success is visible. A stronger financing ecosystem could help founders turn scientific capability into durable technology businesses.

Venture capital is private investment in young companies that could grow substantially but may also fail. Investors usually accept uncertainty in exchange for a potential financial return. The article focuses on whether Indian VCs accept enough uncertainty when technologies are still being tested.

An established revenue company offers evidence that customers want its product and that its business model functions. An unproven scientific experiment offers no such certainty. Investors must assess the science, team, testing plan, and technical risks. Dognosis, for example, needs clinical validation and regulatory approvals before meaningful revenue may become possible.

That difference changes the investment approach. Deeptech requires capital for experiments, prototypes, testing, and validation, often before commercial traction exists. The article calls this financing distinct from backing a technology after it works. Both forms are needed, but the earlier one demands greater patience and technical understanding.